453566-03-5Relevant academic research and scientific papers
TOPICAL PHARMACEUTICAL COMPOSITIONS COMPRISING IMIDAZO[1,2-B]PYRIDAZINE COMPOUNDS
-
Page/Page column 79, (2021/07/31)
The present invention relates to pharmaceutical compositions, such as topical pharmaceutical compositions, comprising certain imidazo[1,2-b]pyridazine compounds and the pharmaceutically acceptable salts and/or solvates of such compounds. The invention als
IMINO SULFANONE INHIBITORS OF ENPP1
-
Paragraph 0202, (2021/11/13)
The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine- based inhibitors of ENPP1 of Formula (I) and methods of their use for treating disease mediated by ENPP1.
IMIDAZO[1,2-B]PYRIDAZINES AS TRK INHIBITORS
-
Page/Page column 73; 74, (2020/03/16)
The present invention relates to certain imidazo[1,2-b]pyridazine compounds and the pharmaceutically acceptable salts of such compounds. The invention also relates to the processes for the preparation of the compounds, compositions containing the compound
DI(HETERO)ARYLCYCLOHEXANE DERIVATIVES, THEIR PREPARATION, THEIR USE AND PHARMACEUTICAL COMPOSITIONS COMPRISING THEM
-
Page/Page column 135-136, (2009/01/24)
The present invention relates to di(hetero)arylcyclohexane derivatives of the formula (I), in which Ar1, Ar2, R1 and R2 have the meanings indicated in the claims. The compounds of the formula (I) are valuable pharmaceutical active compounds which inhibit ATP-sensitive potassium channels in the heart muscle and are suitable, for example, for the treatment of disorders of the cardiovascular system such as arrhythmias or a decreased contractility of the heart, such as can occur, for example, in coronary heart disease, cardiac insufficiency or cardiomyopathies. In particular, they are suitable for the prevention of sudden cardiac death. The invention furthermore relates to processes and intermediates for the preparation of the compounds of the formula (I), their use and pharmaceutical compositions comprising them.
3, 5-DISUBSTITUTED PHENYL-PIPERIDINES AS MDULATORS OF DOPAMINE? NEUROTRANSMISSION
-
Page/Page column 15; 20, (2010/11/27)
The present invention relates to compounds having therapeutic effects against disorders in the central nervous system, and in particular substituted phenylpiperidines of the Formula (1) wherein R is as defined herein.
PROCESS FOR THE SYNTHESIS OF 4-(3-SULFONYLPHENYL)-PIPERIDINES
-
Page/Page column 21, (2010/11/08)
The present invention is directed to processes for the preparation of 4-(sulfonylphenyl)-piperidines of the Formula (VI), and pharmaceutically acceptable salts thereof; which comprises oxidizing a sulfide of the Formula (VII) or Formula (VIII), to give a
MODULATORS OF CELLULAR ADHESION
-
Page/Page column 114, (2010/02/11)
The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R1-R4, n, p, A, B, D, E, L and AR1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
